Aerbio's pilot line breaks new ground in sustainable biotechnology

Biotech firm, Aerbio, has announced plans to raise up to €50 million in a Series A funding round, an ambitious move that will fuel the construction of its cutting-edge demonstration-scale facility and expand the company's revolutionary (R)evolve platform, setting the stage for full-scale commercial operations.

Aerbio is at the forefront of biotechnology innovation, transforming simple molecules into valuable products without the need for arable land or fossil fuels. With its (R)evolve platform, it has unlocked the potential of microbiology to convert carbon dioxide and hydrogen into valuable products. The company's launching product is Proton, a protein-rich ingredient poised to revolutionize food and animal nutrition industries.

"Our ambition knows no bounds," commented Kaspar Kristiansen, CEO of Aerbio. "Our Series A funding is a bold statement in our conviction in our plan and our relentless pursuit of breaking new ground in biotechnology. We're not just building a company—we're turning biotechnology on its head, paving the way for a sustainable future where sugar-free fermentation is a reality."

Aerbio's approach offers several key advantages. By utilizing renewable resources like carbon dioxide and hydrogen, Aerbio's technology reduces reliance on traditional agriculture and fossil fuels. Its fermentation processes are highly efficient, allowing for the production of valuable products with minimal waste. The company's technology is also designed to be scalable, enabling it to meet increasing demand for sustainable products. Aerbio's platform can be used to produce a wide range of products, including proteins, enzymes, and biofuels.

The funds raised in this round will be crucial in completing its demonstration-scale facility, a pivotal milestone in Aerbio's journey. This facility will provide the final validation needed before scaling up to full commercial operations. With the successful launch of the pilot facility and the recent appointment of board members, Aerbio has strong foundations to build upon, with ambitions to not just become a market leader in sustainable protein solutions, but in the field of industrial biotechnology.

Rob Mansfield, CTO of Aerbio, added, “Behind the scenes, an extraordinary amount of hard work and dedication has been invested into bringing this pilot online. We successfully navigated a number of significant challenges over the past couple of years, and it is a true testament to the team’s commitment that we have been able to deliver such an outstanding result.”

With the support of its investors and the dedication of its team, Aerbio is well-positioned to achieve its ambitious goals. The company's focus on innovation, sustainability, and scalability will continue to drive its growth and success.